Pfizer Inc. (NYSE:PFE) Shares Sold by Ceera Investments LLC

Ceera Investments LLC lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 46.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,903 shares of the biopharmaceutical company's stock after selling 27,930 shares during the period. Ceera Investments LLC's holdings in Pfizer were worth $918,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Trifecta Capital Advisors LLC increased its stake in shares of Pfizer by 3.7% in the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company's stock valued at $305,000 after purchasing an additional 325 shares during the period. Confluence Wealth Services Inc. increased its position in Pfizer by 0.5% in the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company's stock valued at $2,158,000 after acquiring an additional 342 shares during the period. Carr Financial Group Corp raised its stake in Pfizer by 3.3% during the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company's stock valued at $344,000 after acquiring an additional 355 shares in the last quarter. Advisor OS LLC boosted its position in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company's stock worth $1,013,000 after acquiring an additional 365 shares during the period. Finally, Safeguard Investment Advisory Group LLC grew its stake in shares of Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company's stock worth $288,000 after purchasing an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.5 %

NYSE PFE traded up $0.44 on Wednesday, hitting $28.82. 38,360,544 shares of the company were exchanged, compared to its average volume of 43,053,043. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The firm has a market capitalization of $163.28 billion, a P/E ratio of -480.25, a price-to-earnings-growth ratio of 1.20 and a beta of 0.63. The company's 50 day moving average price is $27.10 and its 200-day moving average price is $28.03.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The firm's quarterly revenue was down 19.5% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.83%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer's payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. BMO Capital Markets restated an "outperform" rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, May 2nd. Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Finally, Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective on the stock. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average price target of $35.86.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.